Please provide your email address to receive an email when new articles are posted on . The newly presented data is from the two STOP-HS trials, both of which met their primary endpoints. Povorcitinib ...
Please provide your email address to receive an email when new articles are posted on . Continued lecanemab treatment linked to significant disease-modifying effects. No new safety signals were ...
VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...
The majority of patients with early-stage disease Alzheimer’s disease (AD) had stable or improved cognition over roughly 1 year of treatment with lecanemab (Leqembi), a real-world analysis showed. The ...
Venetoclax-obinutuzumab therapy shows sustained PFS and OS benefits over chemoimmunotherapy in untreated CLL patients with coexisting conditions. The CLL14 trial's 6-year follow-up confirms >50% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback